Welcome to our dedicated page for Rcm Tech SEC filings (Ticker: RCMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RCM Technologies, Inc. (RCMT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. RCM, a Nevada corporation whose common stock trades on the Nasdaq Capital Market, submits annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy materials such as the definitive proxy statement on Schedule 14A.
In its periodic reports, RCM presents consolidated financial statements and segment information for its Specialty Health Care, Engineering and Life Sciences, Data and Solutions businesses. These filings detail revenue, cost of services, gross profit, operating income, net income, balance sheet data and cash flows, along with discussions of risk factors and management’s analysis of results. The company also discloses its use of non-GAAP measures—Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share—and provides reconciliations to the most directly comparable GAAP figures.
Current reports on Form 8-K for RCM include items such as quarterly earnings press releases furnished under Item 2.02 and changes in the company’s independent registered public accounting firm under Item 4.01. One filing describes the dismissal of WithumSmith+Brown, PC and the engagement of EisnerAmper LLP to audit the company’s financial statements and internal control over financial reporting for a specified fiscal year, as well as the remediation of a previously reported material weakness in certain IT general controls.
The company’s definitive proxy statement (DEF 14A) outlines governance and shareholder matters, including the election of directors, approval of an omnibus equity compensation plan, ratification of the independent accountants, and advisory votes on executive compensation and the frequency of such votes. It also explains voting procedures, record dates, quorum requirements and how stockholders can attend and vote at the virtual annual meeting.
On this page, Stock Titan pairs RCM’s SEC filings with AI-powered summaries to help readers quickly understand the key points in lengthy documents. Filings are updated as they are made available on EDGAR, allowing investors to review RCMT’s financial reporting, auditor changes, executive compensation disclosures and other regulatory information in one place, with plain-language explanations of complex sections.
Michael Saks, Division President, Healthcare Services at RCM Technologies, reported a sale of 5,000 shares of RCM Technologies common stock on 08/26/2025 at a reported price of $27.50 per share. After the transaction, the filing shows the reporting person beneficially owns 109,547 shares. The filing also notes 393 shares were acquired under the issuer's Employee Stock Purchase Plan since the most recent Section 16 filing.
The sale is reported as a nondiscretionary transaction executed under a plan established to satisfy Rule 10b5-1 requirements, indicating the disposition followed a prearranged plan rather than an ad hoc decision. The Form 4 lists the reporting person as an officer of the company and is filed by one reporting person.
RCM Technologies (RCMT) submitted a Form 144 reporting a proposed sale of 260,856 shares of common stock through Baird on the NASDAQ with an aggregate market value of $6,850,000. The filing lists 7,410,510 shares outstanding, and the securities to be sold were acquired as restricted share vesting under equity compensation on 01/15/2021 (125,000), 01/03/2023 (125,000) and 01/16/2023 (50,000). The filer reports no sales in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information.
RCM Technologies (RCMT) files a Form 144 reporting a proposed sale of 5,000 shares of common stock, with an aggregate market value of $137,500, to be sold approximately on 08/26/2025 on NASDAQ. The filing shows the shares were acquired through the company’s Employee Stock Purchase Plan on six dates between 2014 and 2022 and the listed acquisition lot quantities sum to 5,000 shares. No securities of the issuer were reported sold by the filer in the past three months. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer.